The Journal of dermatological treatment · 2026
'Oral isotretinoin plus desloratadine for acne vulgaris: an updated global meta-analysis of efficacy, safety, and patient-centered outcomes'.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alrubaiaan Mishari Tariq, Bajamaan Reem, Altuwaijri Alwaleed Mohammed, Alsenidi Reem, Almarzoq Mohammed Saleh, Alashgar Tala Magdy, Alghubaywi Faisal, Bashihab Rahaf
Аннотация
BACKGROUND: Acne vulgaris is a common skin disorder that negatively affects adolescents' quality of life. Recent evidence suggests that combining isotretinoin with desloratadine may enhance treatment outcomes.
OBJECTIVE: To evaluate the efficacy and safety of oral isotretinoin plus desloratadine compared with isotretinoin monotherapy in acne vulgaris patients.
METHODS: A systematic search in PubMed, Web of Science, and CENTRAL was conducted until August 2025, encompassing nine clinical trials with 608 patients. Risk of bias was assessed using the ROB-2 tool, and data were analyzed with RevMan version 5.4.1.
RESULTS: Combination therapy significantly reduced GAGS scores at 4 weeks (MD: -2.53; 95% CI: -4.10 to -0.96; p = 0.002), 12 weeks (MD: -3.62; 95% CI: -4.98 to -2.26; p < 0.00001), 16 weeks (MD: -2.13; 95% CI: -3.43 to -0.84; p = 0.001), and 24 weeks (MD: -2.52; 95% CI: -3.58 to -1.46; p < 0.00001). Clinical efficacy (>90% GAGS reduction) was higher with combination therapy (OR: 2.39; 95% CI: 1.19 to 4.78; p = 0.01). In addition, combination therapy was associated with reduced flare-ups (OR: 0.38; p = 0.009) and pruritus (OR: 0.13; p < 0.00001). Patient satisfaction was greater, with no significant changes observed in laboratory safety parameters.
CONCLUSION: Isotretinoin with desloratadine offers superior efficacy and tolerability, ensuring higher patient satisfaction without safety risks.
OBJECTIVE: To evaluate the efficacy and safety of oral isotretinoin plus desloratadine compared with isotretinoin monotherapy in acne vulgaris patients.
METHODS: A systematic search in PubMed, Web of Science, and CENTRAL was conducted until August 2025, encompassing nine clinical trials with 608 patients. Risk of bias was assessed using the ROB-2 tool, and data were analyzed with RevMan version 5.4.1.
RESULTS: Combination therapy significantly reduced GAGS scores at 4 weeks (MD: -2.53; 95% CI: -4.10 to -0.96; p = 0.002), 12 weeks (MD: -3.62; 95% CI: -4.98 to -2.26; p < 0.00001), 16 weeks (MD: -2.13; 95% CI: -3.43 to -0.84; p = 0.001), and 24 weeks (MD: -2.52; 95% CI: -3.58 to -1.46; p < 0.00001). Clinical efficacy (>90% GAGS reduction) was higher with combination therapy (OR: 2.39; 95% CI: 1.19 to 4.78; p = 0.01). In addition, combination therapy was associated with reduced flare-ups (OR: 0.38; p = 0.009) and pruritus (OR: 0.13; p < 0.00001). Patient satisfaction was greater, with no significant changes observed in laboratory safety parameters.
CONCLUSION: Isotretinoin with desloratadine offers superior efficacy and tolerability, ensuring higher patient satisfaction without safety risks.